No Data
No Data
Beijing Konruns Pharmaceutical (603590.SH) renews their house rental contract.
On July 3, Gelonhui reported that Beijing Konruns Pharmaceutical (603590.SH) signed a house rental contract with its affiliate. The contract for the rental property located at Building 4, No.7 Science Park Road, Life Science Park, Changping District, Beijing, will expire on June 30, 2024. In order to ensure the company's research and office needs, the company renewed the house rental contract with Konruns Pharmaceuticals and continued to rent the property at 2-5 floors, Building 4, No. 7 Science Park Road, Life Science Park, Changping District, Beijing. The rental area is 4,015.45 square meters, and the lease term is three years from July 1, 2024 to June 30, 2027.
Beijing Konruns Pharmaceutical (603590.SH) will distribute a dividend of 3 yuan per 10 shares in 2023, with a registration date of July 3rd.
Zhicheng Finance APP News, Beijing Konruns Pharmaceutical (603590.SH) announced that the company will distribute annual equity for the year 2023, with a cash dividend of 3 yuan (including tax) per 10 shares. The record date is July 3.
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
Kangchen Pharmaceutical (603590.SH): Awarded the Eighth Batch of National Manufacturing Individual Champion Enterprises
Gelonghui, May 20, 丨 Kangchen Pharmaceutical (603590.SH) announced that according to the “Guiding Opinions on Accelerating the Cultivation and Development of Quality Manufacturing Enterprises” and “Notice of the General Office of the Ministry of Industry and Information Technology on Carrying Out the 2023 Manufacturing Industry Champion Enterprise Selection, Certification and Evaluation Work”, etc., after Beijing Kangchen Pharmaceutical Co., Ltd., formal review by the Beijing Federation of Industrial Economics and Information Technology, inspection and recommendation by the Beijing Municipal Bureau of Economy and Information Technology, and the Ministry of Industry and Information Technology organized the China Industrial Economics Federation and other third party agencies to verify, verify, and publicize procedures, etc. The company relied on viper blood clotting enzyme (trade name:”
Gelonghui announcement selection | Bull Group: 2023 net profit of 3.87 billion yuan, up 21.37% year on year; CNOOC: net profit of 39.719 billion yuan in the first quarter, up 23.7% year on year
[Performance Data] Kangchen Pharmaceutical (603590.SH): Net profit attributable to parent increased by 48.24% to 150 million yuan in 2023. Kangchen Pharmaceutical (603590.SH) will release the 2023 annual report. In 2023, the company achieved operating income of 920 million yuan, an increase of 6.15% over the same period of the previous year; net profit attributable to owners of the parent company was 150 million yuan, an increase of 48.24% over the same period last year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 127 million yuan, an increase of 42.51 million yuan over the same period of the previous year %; basic earnings per share 0.
Kangchen Pharmaceutical (603590.SH): Net profit of 41.6543 million yuan in the first quarter increased 62.28% year-on-year
Gelonghui, April 25, 丨 Kangchen Pharmaceutical (603590.SH) released its report for the first quarter of 2024, achieving operating income of 199 million yuan, an increase of 20.67%; net profit attributable to shareholders of listed companies was 41.6543 million yuan, an increase of 62.28% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 39.6567 million yuan, an increase of 74.63% year on year; basic earnings per share were 0.27 yuan.
No Data